This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Secondary uses of electronic health record data in life sciences | Whitepaper


Secondary uses of electronic health record (EHR) data in life sciencesMost Life Sciences (LS) research & development functions are under increasing pressure to improve innovation, reduce development inefficiencies and advance product safety. Patient-level data, collected through Electronic Health Record (EHR) systems, offers one promising avenue for redefining Research & Development (R&D) and revolutionizing the LS value chain. Globally–aggregated, patient-level data could support the identification of disease mechanisms and new discovery areas, accelerate the termination of unsuccessful compounds, decrease patient recruitment cycle times for clinical trials, and improve drug safety surveillance through continuous monitoring. Although it has potential for the entire enterprise, this paper focuses specifically on how EHR data can improve research, development and post-marketing surveillance.

  • We need to have more proactive drug safety surveillance—how can we detect drug safety issues earlier to protect our patients?”
  • Our trial recruitment cycle time is too long—how can we improve it?
  • Our discovery and validation programs are no longer delivering—how can we change our methods?
  • We need to find new sources of competitive advantage—how can we collaborate more effectively with hospitals and other payor organizations?

This article will help you think through ways to effectively apply externally-sourced, patient-level data to inform decisions along the product lifecycle.

Page Last Updated



Stay connected:
Get connected
Share your comments
More on Deloitte Luxembourg
Learn about our site

Recently published